Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EBITDA: 2020-2024

Historic EBITDA for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to -$195.9 million.

  • Prime Medicine's EBITDA rose 3.60% to -$50.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.3 million, marking a year-over-year increase of 9.93%. This contributed to the annual value of -$195.9 million for FY2024, which is 0.96% up from last year.
  • Latest data reveals that Prime Medicine reported EBITDA of -$195.9 million as of FY2024, which was up 0.96% from -$197.8 million recorded in FY2023.
  • Over the past 5 years, Prime Medicine's EBITDA peaked at -$3.4 million during FY2020, and registered a low of -$197.8 million during FY2023.
  • Moreover, its 3-year median value for EBITDA was -$195.9 million (2024), whereas its average is -$171.9 million.
  • Per our database at Business Quant, Prime Medicine's EBITDA slumped by 4,750.26% in 2021 and then climbed by 26.13% in 2022.
  • Prime Medicine's EBITDA (Yearly) stood at -$3.4 million in 2020, then plummeted by 4,750.26% to -$165.4 million in 2021, then climbed by 26.13% to -$122.2 million in 2022, then plummeted by 61.87% to -$197.8 million in 2023, then grew by 0.96% to -$195.9 million in 2024.